Toba Hiroaki, Sakiyama Shoji, Takizawa Hiromitsu, Tangoku Akira
Department of Thoracic and Endocrine Surgery and Oncology, Institute of Health Biosciences, University of Tokushima Graduate School.
J Med Invest. 2016;63(1-2):149-51. doi: 10.2152/jmi.63.149.
Gefitinib and/or erlotinib-induced hepatotoxicity sometimes lead to treatment failure in EGFR mutation-positive patients with non-small cell lung cancer (NSCLC), even though the therapeutic effect is evident.
Here, we report three postoperative NSCLC patients with recurrences who experienced severe hepatotoxicity while receiving gefitinib and/or erlotinib treatment but could be safely switched to afatinib treatment.
Afatinib could be a well-tolerated EGFR-TKI that could be chosen for its relatively low hepatotoxicity, which is attributable to its having a different metabolic mechanism compared to other EGFR-TKIs.
吉非替尼和/或厄洛替尼引起的肝毒性有时会导致表皮生长因子受体（EGFR）突变阳性的非小细胞肺癌（NSCLC）患者治疗失败，尽管其治疗效果显著。
在此，我们报告3例术后复发的NSCLC患者，他们在接受吉非替尼和/或厄洛替尼治疗时出现严重肝毒性，但可安全换用阿法替尼治疗。
阿法替尼可能是一种耐受性良好的表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI），因其肝毒性相对较低而可被选用，这归因于其与其他EGFR-TKI具有不同的代谢机制。
Zotero 插件